A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme.
Location: Spain, Catalonia, Barcelona
Employees: 1-10
Total raised: $1.4M
Founded date: 2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.05.2023 | Seed | $1.4M | Banco Saba... |
Mentions in press and media 3
| Date | Title | Description |
| 11.05.2023 | Oniria Therapeutics cierra una ronda semilla de €1,28M liderada por Mind the Gap. Participan BStartup, business angels, Startup ACCIÓ y otros | 11/05/2023 Nota de prensa ONIRIA THERAPEUTICS CIERRA UNA RONDA SEMILLA DE €1,28M LIDERADA POR MIND THE GAP. PARTICIPAN BSTARTUP, BUSINESS ANGELS, STARTUP ACCIÓ Y OTROS Oniria Therapeutics ha cerrado una ronda de inversión semilla por un ... |
| 11.05.2023 | Oniria Therapeutics Raises €1.28M in Seed Funding | Oniria Therapeutics, a Barcelona, Spain-based biotechnology company that develops drugs for eliminating persistent tumour cells that remain after conventional treatment, raised €1.28M in Seed funding. The round was led by Mind the Gap, the ... |
| - | Oniria Therapeutics | “Modulating cell dormancy to overcome cancer persistence” |